SAN DIEGO, California, July 14 --
With the recent FDA approval of the new P2Y12 inhibitor, prasugrel (Effient),
Accumetrics, Inc. announces that its VerifyNow P2Y12 Test is not only able to
assess response to Plavix(R), but also its newly approved competitor, Effient.
In obtaining a result from the VerifyNow System, physicians are provided
objective information to determine the response of an individual patient to
their antiplatelet therapy, regardless of the P2Y12 inhibitor that is
prescribed.
We are very excited with our product position and timing with the release of
this therapeutic alternative to Plavix, said Timothy I. Still, President and CEO
of Accumetrics. We feel the VerifyNow System can dramatically contribute to a
physician’s ability to enhance care for patients undergoing percutaneous
coronary intervention and receiving the antiplatelet therapy that follows. In
having this alternative therapy, physicians can now utilize the results of the
VerifyNow System to assist in the selection of the therapy that best achieves
the desired antiplatelet effect.
Accumetrics’ VerifyNow P2Y12 Test is used to measure the level of P2Y12
receptor blockade and has been in used globally to assess a patient’s
response to both clopidogrel and prasugrel in clinical trials as well as in
clinical practice within the hospital and physician office settings.
About Accumetrics (www.accumetrics.com)
Accumetrics is committed to advancing medical understanding of platelet
function and enhancing quality of care for patients receiving antiplatelet
therapies by providing industry-leading and widely accessible diagnostic tests
for rapid platelet function assessment.
Accumetrics’ VerifyNow System is the first rapid and easy to use platform
for measuring an individual’s response to multiple antiplatelet agents.
Addressing every major antiplatelet drug, including FDA-cleared products for
aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient) and clopidogrel (Plavix)),
and the GP IIb/IIIa inhibitors (e.g. ReoPro(R) and Integrilin(R)), the VerifyNow
System provides a valuable tool to help physicians make informed treatment
decisions.
The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics,
Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a
registered trademark of Millennium Pharmaceuticals. Plavix is a registered
trademark of Sanofi-Aventis. Effient is a registered trademark of Lilly-Daiichi
Sankyo.
CONTACT: Jules Abraham Lippert/Heilshorn Associates +1-212-838-3777
jabraham@lhai.com Timothy I. Still President and CEO Accumetrics +1-858-404-8260
press@accumetrics.com
SOURCE: Accumetrics
Jules Abraham of Lippert/Heilshorn Associates, +1-212-838-3777,
jabraham@lhai.com for Accumetrics; or Timothy I. Still, President and CEO of
Accumetrics, +1-858-404-8260, press@accumetrics.com
Comments